UnknownNot Applicable

The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

South Korea100 participantsStarted 2006-03

Plain-language summary

PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.

Who can participate

Age range20 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with extraesophageal manifestation symptoms of GERD Exclusion Criteria: * laryngeal, pharyngeal, liver, lung, renal, or hematological disorders * a history of gastrointestinal surgery, and a history of connective tissue disorders. * patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy

What they're measuring

Symptom responders after PPI trials

Timeframe: 2 weeks after PPI trials

Trial details

NCT IDNCT00539786

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-04

Contact for this trial

Tae ggon Kim

+82-2-3410-2975 tggo.kim@samsung.com

View on ClinicalTrials.gov More Gastroesophageal Reflux Disease trials